Table 2.
Predictors for 3-month prognosis in derivation cohort.
| Univariate | Multivariate 1 | Multivariate 2 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | |
| Female | 1.42 | 0.64–3.143 | 0.383 | ||||||
| Age (years) | 1.02 | 1.00–1.05 | 0.030 | ||||||
| Liver cirrhosis | 2.63 | 1.44–4.80 | 0.002 | 2.41 | 1.10–5.27 | 0.028 | 2.65 | 1.18–5.93 | 0.018 |
| Etiology | |||||||||
| HBV infection only | 1 | – | – | ||||||
| HBV infection plus other precipitating factors | 0.94 | 0.57–1.56 | 0.802 | ||||||
| HBV DNA (log10 IU/mL) | 1.02 | 0.89–1.17 | 0.803 | ||||||
| HBV DNA ≥ 3 log10 IU/mL | 1.30 | 0.70–2.40 | 0.402 | ||||||
| Antiviral agents | 0.93 | 0.59–1.45 | 0.745 | ||||||
| Duration of antiviral therapy | |||||||||
| ≥ 2 weeks | 1 | – | – | ||||||
| < 2 weeks | 1.11 | 0.68–1.82 | 0.677 | ||||||
| Total bilirubin (μmol/L) | 1.01 | 1.00–1.01 | 0.000 | 1.01 | 1.00–1.01 | 0.000 | 1.01 | 1.00–1.01 | 0.000 |
| Direct bilirubin (μmol/L) | 1.00 | 1.00–1.01 | 0.032 | ||||||
| Alanine aminotransferase (IU/L) | 1.00 | 1.00–1.00 | 0.573 | ||||||
| Aspartate aminotransferase (IU/L) | 1.00 | 1.00–1.00 | 0.638 | ||||||
| Albumin (g/L) | 0.96 | 0.91–1.03 | 0.246 | ||||||
| Globulin (g/L) | 1.00 | 0.99–1.01 | 0.784 | ||||||
| Serum creatinine (× ULN)a | 3.034.25 | 2.15–8.42 | 0.000 | ||||||
| Serum sodium (mmol/L) | 0.96 | 0.91–1.01 | 0.146 | ||||||
| Serum potassium (mmol/L) | 1.13 | 0.66–1.92 | 0.652 | ||||||
| Serum chloride (mmol/L) | 0.98 | 0.95–1.02 | 0.328 | ||||||
| Venous blood ammonia (mmol/L) | 1.01 | 1.00–1.01 | 0.013 | ||||||
| PT-INR | 4.93 | 2.98–8.15 | 0.000 | 3.55 | 2.04–6.20 | 0.000 | 3.86 | 2.15–6.94 | 0.000 |
| Hemoglobin (g/L) | 0.98 | 0.97–1.00 | 0.032 | ||||||
| Platelets (× 109/L) | 0.99 | 0.98–0.99 | 0.000 | ||||||
| White blood cells (× 109/L) | 1.13 | 1.03–1.23 | 0.008 | ||||||
| Infection | 3.26 | 1.84–5.79 | 0.000 | 1.70 | 1.18–2.45 | 0.005 | 1.87 | 1.28–2.73 | 0.001 |
| Hepatic encephalopathy | 8.86 | 4.61–17.02 | 0.000 | 4.51 | 2.18–9.31 | 0.000 | 4.13 | 1.94–8.83 | 0.000 |
| Sessions of ALSS therapy | 0.75 | 0.64–0.87 | 0.000 | 0.72 | 0.60–0.85 | 0.000 | |||
HR hazard ratio, CI confidence interval, HBV hepatitis B virus, PT-INR international normalized ratio (INR) of prothrombin time (PT), ULN upper limit of normal, ALSS artificial liver support system.
aSerum creatinine (× ULN) equals to serum creatinine (μmol/L) divided by the upper limit of normal (Male: 106 μmol/L; Female: 88 μmol/L).